ABSTRACT	O
Favipiravir	O
is	O
an	O
oral	O
broad	O
-	O
spectrum	O
inhibitor	O
of	O
viral	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
that	O
is	O
approved	O
for	O
treatment	O
of	O
influenza	O
in	O
Japan	O
.	O

We	O
conducted	O
a	O
prospective	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
multicenter	O
trial	O
of	O
favipiravir	O
for	O
the	O
treatment	O
of	O
COVID	O
-	O
19	O
at	O
25	O
hospitals	O
across	O
Japan	O
.	O

Eligible	O
patients	O
were	O
adolescents	O
and	O
adults	O
admitted	O
with	O
COVID	O
-	O
19	O
who	O
were	O
asymptomatic	O
or	O
mildly	O
ill	O
and	O
had	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
of	O
0	O
or	O
1	O
.	O

Patients	O
were	O
randomly	O
assigned	O
at	O
a	O
1	O
:	O
1	O
ratio	O
to	O
early	O
or	O
late	O
favipiravir	O
therapy	O
(	O
in	O
the	O
latter	O
case	O
,	O
the	O
same	O
regimen	O
starting	O
on	O
day	O
6	O
instead	O
of	O
day	O
1	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
viral	B-PrimaryOutcome
clearance	I-PrimaryOutcome
by	B-TimeFrame
day	I-TimeFrame
6	I-TimeFrame
.	O

The	O
secondary	O
endpoint	O
was	O
change	B-SecondaryOutcome
in	I-SecondaryOutcome
viral	I-SecondaryOutcome
load	I-SecondaryOutcome
by	B-TimeFrame
day	I-TimeFrame
6	I-TimeFrame
.	O

Exploratory	O
endpoints	O
included	O
time	B-OtherOutcome
to	I-OtherOutcome
defervescence	I-OtherOutcome
and	O
resolution	B-OtherOutcome
of	I-OtherOutcome
symptoms	I-OtherOutcome
.	O

Eighty	O
-	O
nine	O
patients	O
were	O
enrolled	O
,	O
of	O
whom	O
69	O
were	O
virologically	O
evaluable	O
.	O

Viral	O
clearance	O
occurred	O
within	O
6	O
days	O
in	O
66	O
.	O
7	O
%	O
and	O
56	O
.	O
1	O
%	O
of	O
the	O
early	O
and	O
late	O
treatment	O
groups	O
(	O
adjusted	O
hazard	O
ratio	O
[	O
aHR	O
]	O
,	O
1	O
.	O
42	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
,	O
0	O
.	O
76	O
to	O
2	O
.	O
62	O
)	O
.	O

Of	O
30	O
patients	O
who	O
had	O
a	O
fever	O
(	O
	O
37	O
.	O
5	O
Â°	O
C	O
)	O
on	O
day	O
1	O
,	O
times	O
to	O
defervescence	O
were	O
2	O
.	O
1	O
days	O
and	O
3	O
.	O
2	O
days	O
in	O
the	O
early	O
and	O
late	O
treatment	O
groups	O
(	O
aHR	O
,	O
1	O
.	O
88	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
81	O
to	O
4	O
.	O
35	O
)	O
.	O

During	O
therapy	O
,	O
84	O
.	O
1	O
%	O
developed	O
transient	O
hyperuricemia	B-UnclearOutcome
.	O

Favipiravir	O
did	O
not	O
significantly	O
improve	O
viral	O
clearance	O
as	O
measured	O
by	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
by	O
day	O
6	O
but	O
was	O
associated	O
with	O
numerical	O
reduction	O
in	O
time	O
to	O
defervescence	O
.	O

Neither	O
disease	O
progression	O
nor	O
death	O
occurred	O
in	O
any	O
of	O
the	O
patients	O
in	O
either	O
treatment	O
group	O
during	O
the	O
28	O
-	O
day	O
participation	O
.	O

(	O
This	O
study	O
has	O
been	O
registered	O
with	O
the	O
Japan	O
Registry	O
of	O
Clinical	O
Trials	O
under	O
number	O
jRCTs041190120	O
.	O
)	O

